Literature DB >> 18537616

Progress in the development of matrix metalloproteinase inhibitors.

GuoGang Tu1, WenFang Xu, HuiMing Huang, ShaoHua Li.   

Abstract

Matrix metalloproteinases (MMPs) are a family of zinc-dependent proteinases involved in the degradation and remodeling of extracellular matrix proteins that are associated with the tumorigenic process. MMPs promote tumor invasion and metastasis, regulating host defense mechanisms and normal cell function.Thus, MMP inhibitors (MMPIs) are expected to be useful for the treatment of diseases such as cancer, osteoarthritis, and rheumatoid arthritis. A vast number of MMPIs have been developed in recent years. With the failure of these inhibitors in clinical trials,more efforts have been directed to the design of specific inhibitors with different Zn-binding groups. This review summarizes the current status of MMPIs, the design of small molecular weight MMPIs , a brief description of available three-dimensional MMP structures, a review of the proposed therapeutic utility of MMPIs, and a clinical update of compounds that have entered clinical trials in humans.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18537616     DOI: 10.2174/092986708784567680

Source DB:  PubMed          Journal:  Curr Med Chem        ISSN: 0929-8673            Impact factor:   4.530


  27 in total

1.  Novel yeast bioassay for high-throughput screening of matrix metalloproteinase inhibitors.

Authors:  Bjoern Diehl; Thorsten M Hoffmann; Nina C Mueller; Jens L Burkhart; Uli Kazmaier; Manfred J Schmitt
Journal:  Appl Environ Microbiol       Date:  2011-10-14       Impact factor: 4.792

Review 2.  Pharmacologic therapy for osteoarthritis--the era of disease modification.

Authors:  David J Hunter
Journal:  Nat Rev Rheumatol       Date:  2010-11-16       Impact factor: 20.543

3.  Gelatin degradation assay reveals MMP-9 inhibitors and function of O-glycosylated domain.

Authors:  Jennifer Vandooren; Nathalie Geurts; Erik Martens; Philippe E Van den Steen; Steven De Jonghe; Piet Herdewijn; Ghislain Opdenakker
Journal:  World J Biol Chem       Date:  2011-01-26

4.  Target-Activated Prodrugs (TAPs) for the Autoregulated Inhibition of MMP12.

Authors:  Amanda Cobos-Correa; Frank Stein; Carsten Schultz
Journal:  ACS Med Chem Lett       Date:  2012-07-14       Impact factor: 4.345

Review 5.  Biologic basis of osteoarthritis: state of the evidence.

Authors:  Charles J Malemud
Journal:  Curr Opin Rheumatol       Date:  2015-05       Impact factor: 5.006

6.  Insights from selective non-phosphinic inhibitors of MMP-12 tailored to fit with an S1' loop canonical conformation.

Authors:  Laurent Devel; Sandra Garcia; Bertrand Czarny; Fabrice Beau; Evelyne LaJeunesse; Laura Vera; Dimitris Georgiadis; Enrico Stura; Vincent Dive
Journal:  J Biol Chem       Date:  2010-09-03       Impact factor: 5.157

7.  Liposome-mediated amplified detection of cell-secreted matrix metalloproteinase-9.

Authors:  Jayati Banerjee; Andrea J Hanson; Erin K Nyren-Erickson; Bratati Ganguli; Anil Wagh; Wallace W Muhonen; Benedict Law; John B Shabb; D K Srivastava; Sanku Mallik
Journal:  Chem Commun (Camb)       Date:  2010-03-22       Impact factor: 6.222

8.  High expression of osteoglycin decreases gelatinase activity of murine hepatocarcinoma Hca-F cells.

Authors:  Xiao-Nan Cui; Jian-Wu Tang; Bo Song; Bo Wang; Shan-Yan Chen; Li Hou
Journal:  World J Gastroenterol       Date:  2009-12-28       Impact factor: 5.742

Review 9.  MMPs and ADAMs/ADAMTS inhibition therapy of abdominal aortic aneurysm.

Authors:  Yongqi Li; Weicheng Wang; Lei Li; Raouf A Khalil
Journal:  Life Sci       Date:  2020-04-10       Impact factor: 5.037

10.  Microwave-assisted synthesis of triple-helical, collagen-mimetic lipopeptides.

Authors:  Jayati Banerjee; Andrea J Hanson; Wallace W Muhonen; John B Shabb; Sanku Mallik
Journal:  Nat Protoc       Date:  2009-12-17       Impact factor: 13.491

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.